Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Plos One|July 30, 2011
Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909Christopher J A Duncan, Susanne H Sheehy, Katie J Ewer, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 24, 2012
ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humansSusanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2017
Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and InfantsCarly M Bliss, Abdoulie Drammeh, Georgina Bowyer, et al.
Plos One|March 26, 2013
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adultsCaroline Ogwang, Muhammed Afolabi, Domtila Kimani, et al.
Blood|July 6, 2022
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesisMarcela A Ferrada, Sinisa Savic, Daniela Ospina Cardona, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 17, 2014
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populationsDomtila Kimani, Ya Jankey Jagne, Momodou Cox, et al.
The Lancet. Infectious Diseases|June 22, 2023
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trialIvan T Lee, Catherine A Cosgrove, Patrick Moore, et al.
The Lancet. Rheumatology|September 1, 2020
COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort studyJessica J Manson, Colin Crooks, Meena Naja, et al.
Vaccine|July 19, 2026
ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responsesNarges Ebrahimi, Philip de Whalley, Nasir Kanji, et al.
Science Immunology|December 15, 2019
Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2Christopher J A Duncan, Benjamin J Thompson, Rui Chen, et al.
Pageof 13